outcomes & promising treatment options following hma failure in patients with hr-mds
Published 1 year ago • 173 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
2:48
validation of iwg 2023 criteria for response to treatment with hma in hr-mds
-
2:16
current and future treatment approaches for hr-mds
-
1:30
the prognostic value of patient-reported outcomes in mds
-
11:33
treatment algorithm for low-risk mds
-
4:28
current and emerging treatment options for mds
-
4:16
how are high risk and low risk mds defined? #mds
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
-
1:40:23
from mds to aml: understanding the pathology, diagnostics, and genetic relationship 10/10/17
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
2:04
state-of-the-art treatment for hr-mds
-
1:27
the role of menin inhibitors in the treatment of hr-mds and aml
-
1:02
emerging treatment options for lower- and higher-risk mds and ongoing trials
-
5:43
pre- and post-allohsct treatment in mds
-
3:31
a summary of the prognostic factors that can influence the outcomes of anti-cd19 car-t in r/r dlbcl
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
2:00
the incorporation of immunotherapy into frontline all treatment
-
1:48
do all patients require maintenance therapy following allosct?
-
2:35
methods of optimizing transplantation in mds
-
1:33
phase i trial results for oral azacitidine and venetoclax in r/r aml
-
2:01
updates in mds diagnosis and prognosis with the ipss-m: personalized medicine in 2023